Vidac Pharma Holding Plc
Research Vidac Pharma Holding Plc (T9G.DE) on Bullrun: market cap EUR 25.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerT9G.DE
- ExchangeXETRA
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 25.06M
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 1.89M
- Free cash flow-GBP 1.73M
Valuation Snapshot
latest market cap is EUR 25.06M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 1.89M | -GBP 1.73M | n/a | 0 | GBP 250.00K | GBP 315.00K | -GBP 633.00K |
| FY2024 | n/a | n/a | n/a | n/a | 0 | n/a | n/a | GBP 1.25M |
| FY2023 | GBP 0 | -GBP 1.28M | -GBP 682.00K | n/a | 0 | GBP 60.00K | GBP 142.00K | -GBP 756.00K |
| FY2022 | GBP 0 | -GBP 643.00K | -GBP 468.00K | n/a | -0.01 | GBP 34.00K | GBP 415.00K | -GBP 748.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 25.06M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Vidac Pharma Holding Plc
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vidac Pharma Holding Plc's market cap?
Vidac Pharma Holding Plc's market capitalization is EUR 25.06M.
What does Vidac Pharma Holding Plc do?
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of medicines for oncologic and dermatologic diseases. The company is developing VDA-1102 ointment, an anti-neoplastic agent that is in Phase 2 clinical trials for triggering apoptosis in cancer cells with minimal effects on surrounding normal cells. It is also developing VDA-1102 IV, an anti-neoplastic agent; and VDA-1275, a potent small molecule new chemical entity that are in preclinical stage for use in the treatment of solid tumors.